Literature DB >> 25337222

A fine decision tree consisted of CK5/6, IMP3 and TTF1 for cytological diagnosis among reactive mesothelial cells, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion.

Jinhai Yan1, Qingzhu Wei2, Wenjing Jian1, Jianghuan Liu2, Hongping Tang1, Juan Ge1, Jie Zhou1, Tong Zhao2.   

Abstract

The utility of combination with CK5/6, IMP3 and TTF1 to differentiate among reactive mesothelial cells (RMs), metastatic adenocarcinoma of lung (LAC) and non-lung (NLAC) origin was investigated by using immunocytochemistry (ICC) and conventional PCR (C-PCR) in pleural effusion. A total of 108 cell blocks (32 RMs, 51 LAC and 25 NLAC were evaluated by ICC for CK5/6, IMP3 and TTF1 protein expression. In addition, we further performed C-PCR for amplification of CK5/6, IMP3 and TTF1 DNA from 28 specimens (9 MAC and 7 RMs, 6 LAC and 6 NLAC) for molecular diagnosis. CK5/6 staining was observed in the majority of reactive specimens (78.1%) and was rare in adenocarcinoma cells (14.5%), whereas the opposite was true for IMP3 and TTF1. We found a high frequency of TTF1 positivity (76.5%) in LAC, but not in NLAC (4.0%); while there was no significant difference of IMP3 expression in LAC (88.2%) and NLAC (88.0%). The 487 bp DNA fragments of IMP3 was expected to be amplified in 6/9 of adenocarcinoma cases showed negative in ICC; and the 394 bp DNA fragments of CK5/6 was also expected to be amplified in 4/7 of RMs cases showed negative in ICC. Consistent with ICC results, there was significant difference of TTF1 expression in the LAC and NLAC compared with IMP3 expression. The combination with CK5/6, IMP3 and TTF1 immunostaining appears to be useful to improve the accuracy of cytological diagnoses between RMs, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion. In addition, C-PCR may act as a useful supplemental approach for ICC, especially negative cases in ICC for differential cytological diagnosis.

Entities:  

Keywords:  CK5/6; IMP3; PCR; TTF1; adenocarcinoma; pleural effusion

Mesh:

Substances:

Year:  2014        PMID: 25337222      PMCID: PMC4203193     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  38 in total

Review 1.  Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer.

Authors:  J J Findeis-Hosey; H Xu
Journal:  Biotech Histochem       Date:  2011-08-15       Impact factor: 1.718

2.  A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development.

Authors:  J Nielsen; J Christiansen; J Lykke-Andersen; A H Johnsen; U M Wewer; F C Nielsen
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  A nested-PCR-based schizodeme method for identifying Leishmania kinetoplast minicircle classes directly from clinical samples and its application to the study of the epidemiology of Leishmania tropica in Pakistan.

Authors:  H A Noyes; H Reyburn; J W Bailey; D Smith
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

4.  Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids.

Authors:  Alaa M Afify; Basim M al-Khafaji
Journal:  Acta Cytol       Date:  2002 Jul-Aug       Impact factor: 2.319

5.  WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.

Authors:  Weijian Zhu; Claire W Michael
Journal:  Diagn Cytopathol       Date:  2007-06       Impact factor: 1.582

6.  The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.

Authors:  Nelson G Ordóñez
Journal:  Am J Surg Pathol       Date:  2003-08       Impact factor: 6.394

7.  Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.

Authors:  Krisztina Z Hanley; Michael S Facik; Patricia A Bourne; Qi Yang; Betsy O Spaulding; Thomas A Bonfiglio; Haodong Xu
Journal:  Cancer       Date:  2008-02-25       Impact factor: 6.860

8.  Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity.

Authors:  Hadi Yaziji; Hector Battifora; Todd S Barry; Harry C Hwang; Carlos E Bacchi; Martin W McIntosh; Steven J Kussick; Allen M Gown
Journal:  Mod Pathol       Date:  2006-04       Impact factor: 7.842

9.  Metastatic and histologic presentations in unknown primary cancer.

Authors:  J S Nystrom; J M Weiner; J Heffelfinger-Juttner; L E Irwin; J R Bateman; R M Wolf
Journal:  Semin Oncol       Date:  1977-03       Impact factor: 4.929

10.  Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma.

Authors:  Valsamo K Anagnostou; Konstantinos N Syrigos; Gerold Bepler; Robert J Homer; David L Rimm
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

View more
  3 in total

1.  Papillary Thyroid Carcinoma Cervical Lymph Node Metastasis with Cystic Change Differentiated from Congenital Cystic Lesions with the Assistance of Immunohistochemistry: A Case Study.

Authors:  Yuanxin Liang; Tao Zuo
Journal:  Head Neck Pathol       Date:  2016-10-21

2.  Diagnostic value of thyroid transcription factor-1 for pleural or other serous metastases of pulmonary adenocarcinoma: a meta-analysis.

Authors:  Yongchun Shen; Caishuang Pang; Konglong Shen; Yanqiu Wu; Diandian Li; Chun Wan; Zenglin Liao; Ting Yang; Lei Chen; Fuqiang Wen
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

3.  Is cell block technique useful to predict histological type in patients with ovarian mass and/or body cavity fluids?

Authors:  Zenta Maseki; Hiroaki Kajiyama; Eri Nishikawa; Tatsunari Satake; Toshiya Misawa; Fumitaka Kikkawa
Journal:  Nagoya J Med Sci       Date:  2020-05       Impact factor: 1.131

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.